- Molecular NameDoxazosin
- SynonymDoxazosin mesilate; Doxazosin mesylate
- Weight451.483
- Drugbank_IDDB00590
- ACS_NO74197-85-8
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.43
- pka6.93
- LogD (pH=7, predicted)0.85
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.83
- LogSw (predicted, AB/LogsW2.0)0.12
- Sw (mg/ml) (predicted, ACD/Labs)0.05
- No.of HBond Donors2
- No.of HBond Acceptors10
- No.of Rotatable Bonds4
- TPSA112.27
- StatusFDA approved
- AdministrationN/A
- PharmacologyA quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.
- Absorption_value100.0
- Absorption (description)Doxazosin is well absorbed
- Caco_2N/A
- Bioavailability63.0
- Protein binding98.9
- Volume of distribution (VD)1.01 L/kg (in young adults, aged approx. 29 years); 1.71 L/kg (elderly, aged 71 years).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensively metabolised in the liver by O-demethylation or hydroxylation. Enterohepatic recycling occurs as a large amount of the drug is excreted in faeces as its metabolites and a small amount of the unchanged drug.
- Half life16~22 h
- ExcretionThe remainder of the drug can be found in urine, approx. 9%. 16% of an oral dose is found as the 6-O-demethylation metabolite, 7% as the 7-O-demethylation metabolite, 5% as the 6′-hydroxy metabolite, and 7% as the 7′-hydroxymetabolite. Other metabolites include 2-piperazinyl and 2-amino compounds.
- Urinary ExcretionN/A
- Clerance1.2 mL/min/kg.
- ToxicitySymptoms of overdose include hypotension.
- LD50 (rat)> 1000 mg/kg
- LD50 (mouse)1000 mg/kg